The effects of CCK-4 on plasma arginine-vasopressin and oxytocin levels in women with and without premenstrual dysphoric disorder

By Le Melleacute do J.M.   Bradwejn J.   Koszycki D.   Bellavance F.   Steinberg S.   Halbreich U.   Legrand J.-M.   Bichet D.G.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 266-266

Elsevier

Access to resources Recommend Favorite

Premenstrual dysphoric disorder: is it simply PMS?

By Endicott J.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 259-259

Elsevier

Access to resources Recommend Favorite

Duloxetine for premenstrual dysphoric disorder: a pilot study

By Mazza Marianna   Harnic Desiree   Catalano Valeria   Janiri Luigi   Bria Pietro  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 4, 2008-03 ,pp. : 517-521

Informa Healthcare

Access to resources Recommend Favorite

Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder

By Freeman E.W.  

CNS Drugs, Vol. 18, Iss. 7, 2004-01 ,pp. : 453-468

Adis International

Access to resources Recommend Favorite

Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder

By Yonkers Kimberly A   Pearlstein Teri  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 979-991

Informa Healthcare

Access to resources Recommend Favorite